BioNTech Results Presentation Deck
Oncology pipeline: Expanded to 11 product candidates in 12 clinical trials.
Drug
class
mRNA
Antibodies
SMIM ³
Platform
12
Fix Vac
(fixed combination of
shared cancer antigens)
iNeST
(patient specific cancer
antigen therapy)
Intratumoral
Immunotherapy
Next-Gen CP²
Immunomodulators
Targeted Cancer
Antibodies
Toll-Like
Receptor Binding
Product
Candidate
BNT111
BNT112
BNT113
BNT114
BNT115
R07198457
(BNT122)
SAR441000
(BNT131)
GEN 1046
(BNT311)
GEN1042
(BNT312)
BNT321
(MVT-5873)
BNT411
Indication (Targets)
advanced melanoma
prostate cancer
HPV16+ head and neck cancer¹
triple negative breast cancer
ovarian cancer¹
1L melanoma
multiple solid tumors
solid tumors (IL-12sc,
IL-15sushi, GM-CSF, IFN a)
multiple solid tumors
(PD-L1x4-1BB)
multiple solid tumors
(CD40x4-1BB)
pancreatic cancer (sLea)
solid tumors (TLR7)
1BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials.
2Checkpoint Inhibitor.
3Small Molecule Immunomodulators.
Pre-
clinical Phase 1
Phase 2
Rights /
Collaborator
fully-owned
(Regeneron)
fully-owned
fully-owned
fully-owned
fully-owned
Genentech
(global 50:50
profit/loss)
Sanofi
(global profit/loss
share)
Genmab
(global 50:50
profit/loss)
fully-owned
fully-owned
↑
BNT111: Clinical data published
in Nature (July 2020);
subsequent announcement of
Regeneron collaboration
BNT114 data update for TNBC-
MERIT trial at ESMO Virtual
Congress 2020
BNT 131 data update from
Phase 1 presented at SITC
BNT311 Interim update from
Phase 1 presented at SITC
BNT411 FPD in Phase 1/2 trial
in ES-SCLC
BIONTECHView entire presentation